AI GRAND ROUNDS

Authors: GEMINI (RESIDENT), GROK (ATTENDING), KIMI (EXPERT) & ANUPAM SINGH MD (Human in loop)

Department of Medicine, Santosh Medical College.

Click here for App | Agentic Grand Rounds Index

Round 1

User:

Stage 1: History & Presentation (Timestamp: 8-9 Months Prior to Admission)
A 51-year-old male international airline flight attendant residing in an Hyderabad (previously active gym-goer, no prior chronic medical illnesses) presents to the emergency department with an 8-month history of progressive bilateral leg and hand numbness, severe distal weakness, 12 kg (25 lbs) unintentional weight loss, and exertional dyspnea.
HPI:
- 9 Months Ago: Experienced a minor Motor vehicle accident with transient lower back discomfort. One month later, developed numbness in both feet and ankles. MRI lumbar spine showed mild disc bulges.
- 6 Months Ago: Numbness progressed up to the knees, accompanied by unsteadiness, frequent falls, and loss of hand grip strength, forcing him to take medical leave. Two outpatient EMGs were reported as normal.
- 1 Month Ago: Developed severe distal lower extremity weakness, muscle wasting, exertional dyspnea, and generalized lymph node enlargement. A third EMG performed at an outpatient neurology center revealed evidence of a demyelinating polyradiculoneuropathy, prompting urgent tertiary ER referral.
ROS: Denies fevers, chills, night sweats, bowel/bladder incontinence, or focal cranial nerve deficits.
PMH: Remote self-limiting episode of transient right foot drop several years ago. Hypertension.

Resident:

Hello, Chief Resident here.

Key Findings:
* 8–9 month subacute, progressive demyelinating polyradiculoneuropathy (severe distal weakness, muscle wasting, sensory deficits).
* Prominent systemic features: 12 kg weight loss, exertional dyspnea, and generalized lymphadenopathy.

Differential Diagnoses:
1. POEMS Syndrome (45%): Highly probable. Demyelinating neuropathy combined with lymphadenopathy (often Castleman disease), weight loss, and dyspnea (secondary to fluid overload/pulmonary hypertension) classic for this dyscrasia.
2. Lymphoma / Paraneoplastic Neuropathy (25%): Generalized lymphadenopathy and systemic B-symptoms raise high suspicion for neuro-lymphomatosis or paraneoplastic syndrome.
3. AL Amyloidosis (15%): Fits progressive severe neuropathy, weight loss, and exertional dyspnea (likely cardiac involvement).
4. CIDP with secondary systemic manifestation (15%): Demyelinating features match, but profound weight loss and lymphadenopathy strongly suggest an underlying systemic etiology over idiopathic CIDP.

Recommended Prioritized Tests:
1. Serum & Urine Protein Electrophoresis with Immunofixation + Serum Free Light Chains: To detect monoclonal paraprotein.
2. Serum VEGF Level: Marked elevation strongly supports POEMS syndrome.
3. Excisional Lymph Node Biopsy: Evaluate for lymphoma vs. Castleman disease.
4. CT Chest/Abdomen/Pelvis with Contrast: Assess lymphadenopathy extent, organomegaly, and effusions.
5. Complete Skeletal Survey (or low-dose whole-body CT): Screen for osteosclerotic lesions.

Attending:

Hello Attending Consultant here

Top 3 DDx:
1. POEMS (osteosclerotic myeloma/Castleman)
2. Neurolymphomatosis/paraneoplastic (NHL)
3. AL amyloidosis (with cardiac/pulmonary involvement)

Critique: Solid prioritization of POEMS given demyelinating polyneuropathy + systemic features, but underweights remote foot-drop (possible prior mononeuritis) and over-relies on outpatient EMGs. CIDP as residual is low-yield without monoclonal protein exclusion. Dyspnea workup incomplete (no echo/PFTs flagged).

5-7 Specific Improvements:
1. Add VEGF + IL-6 immediately with SPEP/IFE/FLC.
2. Urgent excisional (not FNA) LN bx + bone marrow bx.
3. TTE + NT-proBNP for pulmonary HTN/restrictive cardiomyopathy.
4. Low-dose WBCT or PET-CT over plain skeletal survey.
5. Anti-MAG, ganglioside Abs, and CSF (protein, cytology, flow).
6. Quantiferon + HIV/HCV serologies (travel/occupational risks).
7. Nerve ultrasound or repeat EMG with proximal stimulation.

Expert:

Hello, Expert Clinician here.

Best unifying diagnosis: POEMS syndrome — subacute demyelinating polyradiculoneuropathy plus weight loss, generalized lymphadenopathy (often Castleman disease), and dyspnea (pulmonary hypertension/effusions) in a middle-aged man is classic. The remote transient foot drop may have been an early mononeuropathic herald.

Top differentials and fit:
- AL amyloidosis: weight loss and dyspnea fit, but neuropathy is typically axonal with autonomic/painful small-fiber features, not demyelinating.
- Neurolymphomatosis/paraneoplastic NHL: lymphadenopathy fits; however, nerve involvement is usually painful, asymmetric, axonal.
- CIDP: demyelination fits, but two initially normal EMGs and prominent systemic features argue against idiopathic CIDP.

Key pivot: Conversion from two normal EMGs to a frankly demyelinating polyradiculoneuropathy concurrent with emerging lymphadenopathy and dyspnea — reframing a "neuropathy" case into a systemic plasma cell dyscrasia.

Most important next move: SPEP with immunofixation, serum free light chains (lambda predominance), and serum VEGF, paired with excisional lymph node biopsy and low-dose whole-body CT/PET for sclerotic bone lesions.

Teaching pearl: A demyelinating polyneuropathy with systemic symptoms mandates a paraprotein and VEGF workup — POEMS neuropathy is relentlessly progressive, and early EMGs can be deceptively normal.

Round 2

User:

Stage 2: Physical Examination & Initial Laboratory Evaluation (Timestamp: Admission / Day 1)
Physical Exam: Afebrile, HR 82 bpm, BP 124/78 mmHg, SpO2 98% room air.
Generalized Painless Lymphadenopathy: Prominent bilateral cervical, axillary, and inguinal lymph nodes (left axillary node 2.5 cm, firm, non-tender).
Neurologic Exam:
- Cranial Nerves: Intact (II-XII).
- Motor Exam: Normal tone; marked atrophy of first dorsal interossei, biceps, and thigh musculature. Distal upper extremity strength 4/5 (triceps, grip); lower extremity strength 2-3/5 distally (ankle dorsiflexion/plantarflexion) and 3/5 proximally (left hip/knee flexion).
- Sensory Exam: Diminished vibration and proprioception in a length-dependent pattern up to the knees bilaterally.
- Reflexes: Complete lower extremity areflexia (0/4), 1+ brachioradialis. Severe gait ataxia requiring crutches/wheelchair.
Initial Laboratory Panel:
- Hemogram: WBC 13.8 x 10³/µL (mild leukocytosis), Hb 14.2 g/dL, Platelets 280,000/µL.
- Biochemistry: Normal BMP (Serum Creatinine 0.8 mg/dL), normal LFTs, normal ESR (14 mm/hr) and CRP (3.2 mg/L). Elevated Serum Vitamin B12 (>2,000 pg/mL).
- Infectious/Autoimmune Screening: HIV 1/2, HBsAg, Anti-HCV, Syphilis (VDRL), ANA, ANCA all negative.

Resident:

Hello, Chief Resident here.

Updated Key Findings:
* Severe, progressive demyelinating polyradiculoneuropathy with diffuse muscle atrophy and lower extremity areflexia.
* Generalized painless lymphadenopathy (up to 2.5 cm).
* Markedly elevated Vitamin B12 (>2,000 pg/mL), a key surrogate marker often seen in plasma cell dyscrasias and lymphoproliferative disorders.
* Negative initial autoimmune/infectious panel.

Probability-Based Differential Diagnoses:
1. POEMS Syndrome (55%): Demyelinating neuropathy, lymphadenopathy, high B12, and exertional dyspnea strongly fit this plasma cell dyscrasia.
2. Lymphoma / Neurolymphomatosis (25%): Generalized lymphadenopathy with elevated B12 raises strong concern for an underlying non-Hodgkin lymphoma.
3. Castleman Disease with Secondary Neuropathy (10%): Causes generalized lymphadenopathy and neuropathy; tightly linked to POEMS.
4. AL Amyloidosis (10%): Accounts for neuropathy, high B12, and dyspnea, though demyelinating features are atypical.

Prioritized Next Tests:
1. Serum & Urine Immunofixation (SPEP/UPEP) with Free Light Chains: Screen for monoclonal lambda paraprotein.
2. Serum VEGF Level: Critical diagnostic marker for POEMS.
3. Excisional Left Axillary Lymph Node Biopsy: Evaluate for Castleman disease vs. lymphoma.
4. Whole-Body PET-CT / Low-Dose CT: Assess for osteosclerotic bone lesions and organomegaly.
5. Echocardiogram & NT-proBNP: Investigate exertional dyspnea for pulmonary hypertension or cardiac involvement.

Attending:

Hello Attending Consultant here

Top 3 DDx:
1. POEMS (Castleman variant)
2. NHL/neurolymphomatosis
3. AL amyloidosis

Critique: Appropriately elevates POEMS with high B12 as surrogate and painless adenopathy; probabilities refined well. Still under-emphasizes areflexia/ataxia as polyradiculoneuropathy hallmark and omits thrombocytosis absence (common in POEMS). Normal ESR/CRP lowers pure inflammatory CIDP further. Dyspnea remains unaddressed beyond echo.

5-7 Specific Improvements:
1. Add VEGF + IL-6 with SPEP/IFE/sFLC STAT.
2. Excisional axillary LN bx (flow, HHV-8, Castleman histology) + concurrent BM bx.
3. PET-CT for sclerotic lesions/organomegaly over plain CT.
4. TTE + NT-proBNP + PFTs for PH/restrictive physiology.
5. CSF analysis (cytoalbuminologic dissociation, flow, cytology).
6. Anti-MAG/ganglioside panel + nerve US.
7. Quantify lambda light-chain bias and skeletal survey if PET delayed.

Expert:

Hello, Expert Clinician here.

Best unifying diagnosis: POEMS syndrome, Castleman disease variant. Stage 2 data tighten the diagnosis: markedly elevated B12 (a classic surrogate marker of plasma cell dyscrasias and Castleman), generalized painless lymphadenopathy, demyelinating polyradiculoneuropathy with areflexia, and normal inflammatory markers (ESR/CRP characteristically low in POEMS despite systemic illness).

Top differentials and fit:
- Non-Hodgkin lymphoma/neurolymphomatosis: adenopathy and high B12 fit; however, neuropathy is typically asymmetric, painful, axonal — not length-dependent demyelinating.
- AL amyloidosis: high B12 and neuropathy fit, but demyelination and painless bulky adenopathy argue against.
- CIDP: essentially excluded by systemic surrogates and elevated B12.

Key pivot: Markedly elevated B12 — an under-recognized clue — combined with a suppressed ESR/CRP in a systemically ill patient with neuropathy redirects the search toward a plasma cell neoplasm rather than inflammation.

Most important next move: SPEP with immunofixation, serum free light chains, and VEGF level (major POEMS criterion), plus excisional left axillary biopsy with HHV-8 staining and PET-CT for sclerotic lesions.

Teaching pearl: An unexplained, strikingly elevated B12 in a demyelinating polyneuropathy is a red flag for occult malignancy or plasma cell dyscrasia — never dismiss it as supplementation artifact.

Round 3

User:

Stage 3: Lumbar Puncture, EMG & Body CT Imaging (Timestamp: Hospital Days 2-4)
Lumbar Puncture (CSF Analysis):
- Opening Pressure: Normal (14 cm H2O).
- CSF Appearance & Chemistry: Clear; Profound Lymphocytic Pleocytosis (88 cells/µL, 95% Lymphocytes); Undetectably High CSF Protein (>200 mg/dL); normal CSF Glucose (62 mg/dL).
- CSF Microbiology & Serology: CSF Gram stain, bacterial/fungal/AFB cultures negative. Oligoclonal bands positive (2 bands). Paraneoplastic panel negative.
EMG & Nerve Conduction Studies: Confirmed a length-dependent sensorimotor polyradiculoneuropathy with proximal demyelinating features (prolonged F-wave latencies).
CT Chest / Abdomen / Pelvis: Extensive widespread non-bulky lymphadenopathy involving bilateral cervical, axillary, retroperitoneal, mesenteric, iliac, and inguinal lymph node basins. No mediastinal adenopathy or organomegaly.

Resident:

Hello, Chief Resident here.

Updated Key Findings:
* Profound CSF lymphocytic pleocytosis (88 cells/µL) with markedly elevated protein (>200 mg/dL).
* Demyelinating polyradiculoneuropathy on EMG.
* Extensive widespread non-bulky lymphadenopathy.

Diagnostic Pivot & Differential Diagnoses:
The marked CSF pleocytosis significantly challenges classic POEMS or CIDP, which typically exhibit cytoalbuminologic dissociation. This strongly shifts suspicion toward a lymphoproliferative process with direct leptomeningeal or root infiltration (neurolymphomatosis).

  1. Lymphoma / Neurolymphomatosis / Leptomeningeal Lymphoma (55%): High CSF pleocytosis, high protein, diffuse lymphadenopathy, weight loss, and polyradiculopathy render this the top candidate.
  2. Castleman Disease / POEMS Variant (25%): Extensive lymphadenopathy and demyelination remain suspicious, though high CSF WBC is atypical.
  3. Neurosarcoidosis (10%): Can present with widespread lymphadenopathy, severe radiculopathy, high CSF WBC, and protein.
  4. Infectious Polyradiculopathy (10%): Atypical TB, Lyme, or neurotropic viral etiologies.

Prioritized Next Tests:
1. CSF Flow Cytometry & Malignant Cytology: Identify clonal lymphocyte populations.
2. Excisional Lymph Node Biopsy: Histopathology and immunohistochemistry for lymphoma/Castleman.
3. Contrast MRI Whole Spine & Brain: Assess for leptomeningeal/nerve root enhancement.
4. Serum/Urine Immunofixation, sFLC, & VEGF: Rule out co-existing dyscrasia.
5. Bone Marrow Biopsy with Flow Cytometry: Complete staging.

Attending:

Hello Attending Consultant here

Top 3 DDx:
1. Neurolymphomatosis / leptomeningeal NHL
2. POEMS-Castleman (atypical CSF)
3. Neurosarcoidosis

Critique: Correctly pivots on CSF pleocytosis (incompatible with classic CIDP/POEMS cytoalbuminologic dissociation) elevating infiltrative lymphoma; probabilities well-adjusted. Underweights non-bulky diffuse adenopathy without organomegaly (favors low-grade NHL or multicentric Castleman over aggressive lymphoma) and ignores OCB (nonspecific but sarcoid-compatible). EMG proximal demyelination still allows POEMS overlap.

5-7 Specific Improvements:
1. STAT CSF flow cytometry + cytology (x3) + IgH gene rearrangement.
2. Excisional LN bx (not core) with flow, HHV-8, clonality studies + concurrent BM bx.
3. Contrast MRI neuraxis for root/leptomeningeal enhancement.
4. Serum VEGF + SPEP/IFE/sFLC + IL-6 despite atypical CSF.
5. Serum ACE, chest HRCT, and CD4/CD8 ratio if sarcoid rises.
6. PET-CT for occult FDG-avid nodes/marrow.
7. Repeat EMG with root stimulation + nerve US for focal enlargement.

Expert:

Hello, Expert Clinician here.

Best unifying diagnosis: Neurolymphomatosis with leptomeningeal lymphoma. Stage 3 reorients the case: profound lymphocytic pleocytosis (88/µL) with CSF protein >200 mg/dL breaks the cytoalbuminologic dissociation expected in CIDP or POEMS. Combined with diffuse non-bulky lymphadenopathy, polyradiculoneuropathy, and weight loss, this favors clonal lymphoid infiltration of nerve roots and meninges.

Top differentials and fit:
- POEMS-Castleman: adenopathy and demyelination fit, but significant CSF pleocytosis is distinctly atypical.
- Neurosarcoidosis: can produce radiculopathy, adenopathy, and CSF pleocytosis, yet lack of hilar disease, organomegaly, or hypercalcemia weakens support.
- Infectious polyradiculopathy (TB/Lyme): CSF profile fits, but negative stains/cultures, afebrile course, and prominent adenopathy argue against.

Key pivot: CSF lymphocytic pleocytosis — it transforms a presumed demyelinating polyradiculoneuropathy into an infiltrative leptomeningeal process, directing workup toward lymphoma rather than plasma cell dyscrasia.

Most important next move: High-volume CSF cytology ×3 with flow cytometry and IgH/TCR rearrangement, plus contrast MRI of the neuraxis for root/meningeal enhancement, and excisional lymph node biopsy.

Teaching pearl: Albuminocytologic dissociation is expected in immune neuropathies; true CSF pleocytosis should trigger an aggressive search for lymphoma, infection, or granulomatous disease.

Round 4

User:

Stage 4: Excisional Lymph Node Biopsy & Flow Cytometry (Timestamp: Hospital Days 5-7)
Diagnostic Procedures: Excisional biopsy of right axillary lymph node, bone marrow aspirate/biopsy, and CSF flow cytometry.
Histopathology (Right Axillary Lymph Node):
- Capsule effaced by a diffuse proliferation of monomorphic small mature-appearing lymphocytes with intermittent lighter proliferation centers (pseudofollicles / parimmunoblasts).
Flow Cytometry (Lymph Node, Bone Marrow & CSF):
- Identical monoclonal B-cell population across all three compartments: CD5+, CD19+, CD20+, CD200+, Lambda light-chain restricted B-lymphocytes.
Cytogenetics (FISH Analysis):
- Negative for t(11;14) CCND1-IGH translocation (ruling out Mantle Cell Lymphoma).
- Positive for Trisomy 12 (+12) in 56% of cells, confirming Small Lymphocytic Lymphoma / Chronic Lymphocytic Leukemia (SLL/CLL).

Resident:

Hello, Chief Resident here.

Updated Key Findings:
* Lymph node, bone marrow, and CSF flow cytometry confirm identical CD5+, CD19+, CD20+, CD200+, Lambda-restricted B-cell clones.
* Cytogenetics show Trisomy 12 (+12), confirming Small Lymphocytic Lymphoma / Chronic Lymphocytic Leukemia (SLL/CLL) with leptomeningeal/root infiltration (neurolymphomatosis).

Probability-Based Diagnoses:
1. Neurolymphomatosis / Leptomeningeal SLL/CLL (95%): Definitive diagnosis confirmed by matching tissue, bone marrow, and CSF immunophenotyping.
2. Richter’s Transformation (3%): Unlikely given small, mature lymphocytic morphology without diffuse large B-cell features.
3. Paraneoplastic Polyneuropathy (2%): B-cell dyscrasia was primary, but direct neoplastic CSF seeding overrides a purely autoimmune mechanism.

Prioritized Next Steps in Management:
1. Initiate Targeted Systemic Therapy: Urgent start of a BTK inhibitor (e.g., Zanubrutinib, Acalabrutinib, or Ibrutinib) due to high CNS penetration and excellent efficacy in SLL/CLL.
2. Molecular Stratification: Perform TP53 mutation/del(17p) and IGHV mutational status testing to refine prognosis and treatment strategy.
3. Contrast Neuraxis MRI: Spine and brain MRI to establish baseline extent of nerve root and leptomeningeal infiltration.
4. Consider Intrathecal Chemotherapy: Evaluate for IT Methotrexate/Cytarabine if rapid cytoreduction is urgently required.
5. Multidisciplinary Physical Rehabilitation: Intensive PT/OT for gait and motor recovery.

Attending:

Hello Attending Consultant here

Top 3 DDx:
1. SLL/CLL neurolymphomatosis (leptomeningeal/root)
2. Richter transformation (occult large-cell)
3. Concurrent POEMS/Castleman overlap (residual systemic features)

Critique: Correctly locks diagnosis via multi-compartment clonal identity + trisomy 12; probabilities appropriately decisive. Over-relies on empiric BTK start without full risk stratification or Richter exclusion; IT chemo premature given excellent BTK CNS penetration; omits baseline functional staging and TLS prophylaxis.

5-7 Specific Improvements:
1. Urgent PET-CT + LN histology re-review to exclude Richter foci.
2. Complete FISH (del17p/11q) + TP53 NGS + IGHV mutational status pre-therapy.
3. Contrast MRI neuraxis for baseline leptomeningeal burden.
4. Initiate CNS-penetrant BTKi (zanubrutinib preferred) ± venetoclax; defer IT MTX unless progressive deficits.
5. Baseline TTE, PFTs, ophthalmology (vitreoretinal CLL).
6. TLS labs/prophylaxis + IVIG if hypogammaglobulinemia.
7. Serial CSF flow post-cycle 1 for MRD clearance.

Expert:

Hello, Expert Clinician here.

Best unifying diagnosis: Neurolymphomatosis due to CLL/SLL with leptomeningeal and polyradicular infiltration. Identical CD5⁺/CD200⁺ lambda-restricted clones across lymph node, marrow, and CSF, with trisomy 12 and absent t(11;14), confirm a single clonal process driving both the diffuse adenopathy and the demyelinating polyradiculoneuropathy.

Top differentials and fit:
- Richter transformation: possible occult large-cell focus must be excluded (PET-CT, repeat histology), but morphology and mature phenotype argue against.
- POEMS/Castleman overlap: systemic features initially suggested POEMS; however, lambda-restricted B-cell clonality with CSF pleocytosis favors direct lymphomatous infiltration.
- Paraneoplastic neuropathy: unlikely — neoplastic cells are directly demonstrated in CSF.

Key pivot: Multi-compartment flow cytometry proving a shared B-cell clone converts a puzzling "demyelinating neuropathy with adenopathy" into definitive neurolymphomatosis, redirecting therapy from immunomodulation to targeted anti-CLL treatment.

Most important next move: Start a CNS-penetrant BTK inhibitor (preferably zanubrutinib) after baseline PET-CT and TP53/IGHV risk stratification, with serial CSF flow to document clearance.

Teaching pearl: CLL with unexplained neurologic deficits or adenopathy always warrants CSF flow cytometry — lymphomatous neuro-invasion is underdiagnosed and responds dramatically to BTK inhibition.

Round 5

User:

Stage 5: Final Unifying Diagnosis & Clinical Course (Timestamp: Follow-up & Discharge)
Final Unifying Diagnosis: Leptomeningeal Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL / SLL) with Leukemic Meningitis & Secondary Polyradiculopathy (CNS Leukemic Infiltration).
Treatment Plan: Initiation of high-dose systemic Corticosteroids (Dexamethasone taper), targeted oral Bruton's Tyrosine Kinase (BTK) inhibitor Ibrutinib (420mg daily), and serial Intrathecal Chemotherapy (Intrathecal Methotrexate 15mg + Cytarabine).
Outcome: Serial lumbar punctures demonstrated rapid clearance of CSF leukemic cells (pleocytosis dropped from 88 -> 20 -> 11 cells/µL; CSF protein decreased from >200 -> 86 -> 66 mg/dL). Patient experienced dramatic neurological recovery, regaining independent ambulation during physical rehabilitation.

Resident:

Hello, Chief Resident here.

Key Findings & Final Diagnosis:
A dramatic case of Leptomeningeal CLL/SLL with leukemic meningitis and secondary demyelinating polyradiculopathy mimicking POEMS/CIDP. Combined targeted BTKi therapy (Ibrutinib), corticosteroids, and intrathecal chemotherapy achieved rapid CSF clearance and complete functional recovery.

Final Probability-Based Diagnoses:
1. Leptomeningeal CLL/SLL Polyradiculopathy (98%): Confirmed by matching CD5+/CD200+/Trisomy 12 B-cell clones in node, marrow, and CSF, with rapid response to target therapy.
2. Richter Transformation (1%): Excluded by mature histology, non-bulky lymphadenopathy, and durable response.
3. Primary CIDP / POEMS (1%): Fully ruled out by direct malignant CSF infiltration.

Key Next Steps & Management:
1. Maintenance BTKi Therapy: Continue long-term BTK inhibition, monitoring for cytopenias, atrial fibrillation, and bleeding risks.
2. Surveillance: Serial CSF flow cytometry to document complete minimal residual disease (MRD) clearance.
3. Infection Prophylaxis: Maintain PJP and VZV prophylaxis during chemo-immunotherapy.
4. Prognostic Risk Stratification: Finalize TP53 deletion/mutation and IGHV mutational status.
5. Rehabilitation: Continue multidisciplinary physical therapy to consolidate motor and gait recovery.

Attending:

Hello Attending Consultant here

Top 3 DDx:
1. CLL/SLL neurolymphomatosis (confirmed)
2. Occult Richter transformation
3. Therapy-related secondary neuropathy

Critique: Diagnosis locked correctly via multi-site clonality. Plan overuses IT chemo (BTKi alone often suffices for CNS CLL) and selects first-gen ibrutinib (higher AF/bleeding risk) without full TP53/IGHV data. Steroid taper appropriate but lacks explicit TLS/infection prophylaxis detail. Excellent outcome validates approach yet omits long-term MRD and cardiac surveillance.

5-7 Specific Improvements:
1. Switch to zanubrutinib (superior CNS penetration, safer CV profile).
2. Complete TP53 NGS + IGHV status before indefinite BTKi.
3. Limit IT MTX/Ara-C to 2–4 doses if CSF clears rapidly.
4. Baseline/serial ECG + TTE for ibrutinib toxicity.
5. PJP/VZV prophylaxis + IVIG if IgG low.
6. PET-CT at 3 mo to exclude Richter.
7. CSF flow MRD q3mo + structured neuro-rehab metrics.

Expert:

Hello, Expert Clinician here.

Best unifying diagnosis: Leptomeningeal CLL/SLL with polyradiculoneuropathy — a rare neurolymphomatosis variant masquerading as CIDP/POEMS, now confirmed by matched clonality and validated by brisk CSF clearance and near-complete neurologic recovery on ibrutinib, steroids, and IT therapy.

Top differentials and fit:
- Richter transformation: excluded by mature morphology, absence of bulky disease, and sustained response.
- POEMS syndrome: lambda restriction and neuropathy initially mimicked it, but true CSF pleocytosis and B-cell clonality exclude a plasma cell dyscrasia.
- CIDP: definitively refuted by malignant CSF cytology.

Key pivot: Direct demonstration of a CD5⁺/CD200⁺/trisomy-12 clone in CSF — converting an "immune neuropathy" into a treatable infiltrative leukemia, justifying CNS-penetrant therapy rather than IVIG/plasmapheresis.

Most important next move: Transition to a second-generation BTK inhibitor (zanubrutinib) for durable CNS disease control with better cardiovascular safety, complete TP53/IGHV risk stratification, and serial CSF MRD surveillance.

Teaching pearl: Leukemic meningitis can present as a pure demyelinating polyradiculoneuropathy with scant systemic signs; early CSF flow cytometry — not just protein/cell count — is the diagnostic linchpin.

Top 15 Takeaways for Clinicians

  1. Definition of Leptomeningeal Neurolymphomatosis: Leptomeningeal infiltration by Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL) is a rare neuro-oncologic manifestation where malignant B-cell clones infiltrate the subarachnoid space and spinal nerve roots.
  2. Mimicry of Inflammatory Demyelinating Neuropathies: CNS leukemic infiltration frequently presents as a progressive polyradiculopathy resembling Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) or POEMS syndrome.
  3. CSF Pleocytosis Breaks Cytoalbuminologic Dissociation: While immune neuropathies like CIDP show high CSF protein with normal cell counts, true CSF lymphocytic pleocytosis (>50–80 cells/µL) indicates direct meningeal infection or malignancy.
  4. Diagnostic Triad on Flow Cytometry: Identification of an identical monoclonal B-cell population (CD5+, CD19+, CD200+, Lambda light-chain restricted) across lymph node, bone marrow, and CSF confirms neurolymphomatosis.
  5. Trisomy 12 Cytogenetic Landmark: Trisomy 12 (+12) is found in ~20% of CLL/SLL cases; demonstrating +12 on FISH without t(11;14) rules out Mantle Cell Lymphoma.
  6. Diagnostic Value of CSF Flow Cytometry: Standard CSF cytology alone can miss small mature leukemic B-cells; flow cytometry is the gold-standard diagnostic tool for detecting leptomeningeal CLL infiltration.
  7. Painless Generalized Lymphadenopathy Clue: Widespread, non-bulky painless lymphadenopathy (cervical, axillary, retroperitoneal, inguinal) in a patient presenting with progressive neuropathy strongly mandates lymph node biopsy.
  8. Under-recognized Elevated Vitamin B12 Marker: Unexplained marked elevations in serum Vitamin B12 (>2,000 pg/mL) can serve as a surrogate biomarker for underlying lymphoproliferative disorders or haematologic malignancies.
  9. Role of CNS-Penetrant BTK Inhibitors: Small molecule Bruton's Tyrosine Kinase (BTK) inhibitors (such as Ibrutinib or 2nd-generation Zanubrutinib) cross the blood-brain barrier and achieve durable central nervous system clearance.
  10. Serial Intrathecal Chemotherapy: Combining oral BTKi therapy with serial intrathecal chemotherapy (Methotrexate + Cytarabine) achieves rapid cytoreduction of leukemic cells in the subarachnoid space.
  11. Monitoring Minimal Residual Disease (MRD): Serial CSF lumbar punctures with flow cytometry tracking cell counts (dropping from 88 to <10 cells/µL) provide quantifiable metrics of disease response.
  12. Exclusion of Richter Transformation: Any patient with CLL presenting with aggressive or atypical extramedullary symptoms requires PET-CT and biopsy re-review to exclude transformation to Diffuse Large B-Cell Lymphoma (DLBCL).
  13. Molecular Stratification (TP53 and IGHV): Pre-treatment genetic testing for TP53 deletion/mutation and IGHV mutational status is essential to guide long-term targeted therapy selection.
  14. Infection Prophylaxis during BTKi Therapy: Given hypogammaglobulinemia and concurrent chemo-immunotherapy, patients require routine Pneumocystis jirovecii (PJP) and Varicella Zoster (VZV) prophylaxis.
  15. Neurological Recovery Potential: Unlike structural cord compression, leukemic nerve root infiltration responds rapidly to targeted therapy, allowing dramatic motor recovery and restoration of unassisted ambulation.